Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2011

View Archived Issues

TIGEM describes HDAd-based gene therapy for primary hyperoxaluria type 1 / News in Context

Novel neurotransmitter modulators patented

Top-line phase I data on VRS-859 for type 2 diabetes

VBI Vaccines completes acquisition of Epixis

Zofran may be associated with abnormal heart rhythms

Dovitinib assessed in HER2- breast cancer stratified by FGFR1 and HR amplification statuses

Novel treatment strategy for leukemia targets oncogene upregulation

Phase II trial evaluates FV-100 for pain associated with shingles

Novel protein kinase inhibitors patented by DCAM Pharma

Ono Pharmaceutical secures new Japanese approval for Glactiv

Catabasis Pharmaceuticals identifies new NF-kappa-B activation inhibitors

Vivus reaches agreement with FDA on Qnexa NDA

PROLOR Biotech presents promising preclinical data on FVIIa-CTP

BioLineRx receives European confirmation of regulatory pathway for BL-5010

New antivirals described by Gilead Sciences

New curcumin derivatives reported for Alzheimers disease

Alkermes completes merger with Elan Drug Technologies

Phosphagenics set to begin pivotal trials of TPM technology-delivered oxycodone patch

Karo Bio obtains clearance for phase III trial in HeFH

Spinifex Pharmaceuticals commences phase II study of EMA-401

Merck KGaA acquires exclusive worldwide rights to experimental MS treatment

Bioheart to seek FDA clearance for phase I ANGEL study

SMART-5 trial data reported for bazedoxifene/conjugated estrogens

Pronova BioPharma initiates first-in-human study of PRC-4016

Velcade approved in Japan for new indication

Health Canada issues new approval for Lucentis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.